Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.02.05.21250953: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization We conducted several sensitivity analyses to explore the robustness of the findings for the primary hypothesis against the model specifications, such as varying the caliper size by +/-0.1 and changing the matching order from the default maximum distance first to random order with different seeds. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of this study include its …
SciScore for 10.1101/2021.02.05.21250953: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization We conducted several sensitivity analyses to explore the robustness of the findings for the primary hypothesis against the model specifications, such as varying the caliper size by +/-0.1 and changing the matching order from the default maximum distance first to random order with different seeds. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of this study include its retrospective nature, as well as unmeasured variables, such as the exact timing of convalescent plasma administration with respect to the date of COVID-19 diagnosis, the antibody titers/levels in the plasma that was administered, and whether repeat dosing was employed. Despite propensity matching, it is possible that residual confounding remains, and results should be interpreted with caution. For example, even after propensity matching, the convalescent plasma recipients received more corticosteroids and remdesivir. Although these agents have not been shown to have a clear survival benefit in cancer populations,25 it is possible that at least part of the observed protective effect of convalescent plasma could be due to concomitant medications, including fewer administrations of hydroxychloroquine. Convalescent plasma non-recipients may have received less aggressive care overall due to factors other than COVID-19, e.g., advanced states of cancer; this possibility is partially addressed through adjustment for cancer status. Differential access to convalescent plasma due to health system or socioeconomic factors cannot be excluded. It is possible that the findings in the first 30 days would not persist into later periods, which would require a more extended follow-up. Therefore, like any observational study, these findings should not be inferred for causality but rather be seen as contributing to the accumulating evidence regarding survival...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04354701 Recruiting COVID-19 and Cancer Consortium Registry NCT04384588 Recruiting COVID19-Convalescent Plasma for Treating Patients With Activ… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from scite Reference Check: We found no unreliable references.
-
